Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could represent a notable step forward for body loss . Preliminary clinical tests have indicated substantial reductions in abdominal tissue, potentially surpassing other obesity treatments. Despite this, more st